Laminins and cancer stem cells: Partners in crime?

Seminars in Cancer Biology

Volumn 45, Issue , 2017, Pages 3-12

  Qin, Yan ^a   Rodin, Sergey ^b   Simonson, Oscar E ^b,c   Hollande, Frédéric ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Basement membrane; Cancer stem cells; Laminins; Pluripotent stem cells

Indexed keywords

LAMININ;

ADVANCED CANCER; ANGIOGENESIS; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CELL SUBPOPULATION; DRUG RESISTANCE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; MALIGNANT NEOPLASM; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; STEM CELL LINE; STEM CELL NICHE; TUMOR GROWTH; ANIMAL; CANCER STAGING; CELL TRANSFORMATION; CYTOLOGY; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PLURIPOTENT STEM CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; NEOPLASM STAGING; NEOPLASMS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS;

EID: 84994682256     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.07.004     Document Type: Review

References (101)

1. Domogatskaya, A., Rodin, S., Tryggvason, K., Functional diversity of laminins. Annu. Rev. Cell Dev. Biol. 28 (2012), 523–553.
2. Lu, P., Weaver, V.M., Werb, Z., The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196 (2012), 395–406.
3. Patarroyo, M., Tryggvason, K., Virtanen, I., Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin. Cancer Biol. 12 (2002), 197–207.
4. Givant-Horwitz, V., Davidson, B., Reich, R., Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res. 64 (2004), 3572–3579.
5. Miyazaki, T., Futaki, S., Hasegawa, K., Kawasaki, M., Sanzen, N., Hayashi, M., et al. Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells. Biochem. Biophys. Res. Commun. 375 (2008), 27–32.
6. Rodin, S., Antonsson, L., Hovatta, O., Tryggvason, K., Monolayer culturing and cloning of human pluripotent stem cells on laminin-521-based matrices under xeno-free and chemically defined conditions. Nat. Protoc. 9 (2014), 2354–2368.
7. Rodin, S., Antonsson, L., Niaudet, C., Simonson, O.E., Salmela, E., Hansson, E.M., et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat. Commun., 5, 2014, 3195.
8. Rodin, S., Domogatskaya, A., Strom, S., Hansson, E.M., Chien, K.R., Inzunza, J., et al. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat. Biotechnol. 28 (2010), 611–615.
9. Qian, X., Villa-Diaz, L.G., Krebsbach, P.H., Advances in culture and manipulation of human pluripotent stem cells. J. Dent. Res. 92 (2013), 956–962.
10. Kreso, A., Dick, J.E., Evolution of the cancer stem cell model. Cell Stem Cell. 14 (2014), 275–291.
11. Magee, J.A., Piskounova, E., Morrison, S.J., Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21 (2012), 283–296.
12. O'Connor, M.L., Xiang, D., Shigdar, S., Macdonald, J., Li, Y., Wang, T., et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 344 (2014), 180–187.
13. Aumailley, M., Bruckner-Tuderman, L., Carter, W.G., Deutzmann, R., Edgar, D., Ekblom, P., et al. A simplified laminin nomenclature. Matrix Biol. 24 (2005), 326–332.
14. Aumailley, M., The laminin family. Cell Adhes. Migr. 7 (2013), 48–55.
15. Aumailley, M., Smyth, N., The role of laminins in basement membrane function. J. Anat. 193:Pt. (1) (1998), 1–21.
16. Colognato, H., Yurchenco, P.D., Form and function: the laminin family of heterotrimers. Dev. Dyn. 218 (2000), 213–234.
17. Miner, J.H., Yurchenco, P.D., Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 20 (2004), 255–284.
18. Kostourou, V., Papalazarou, V., Non-collagenous ECM proteins in blood vessel morphogenesis and cancer. Biochim. Biophys. Acta 1840 (2014), 2403–2413.
19. Bonnans, C., Chou, J., Werb, Z., Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15 (2014), 786–801.
20. Oikawa, Y., Hansson, J., Sasaki, T., Rousselle, P., Domogatskaya, A., Rodin, S., et al. Melanoma cells produce multiple laminin isoforms and strongly migrate on alpha5 laminin(s) via several integrin receptors. Exp. Cell Res. 317 (2011), 1119–1133.
21. Chiarugi, P., Giannoni, E., Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 76 (2008), 1352–1364.
22. Zetter, B.R., Angiogenesis and tumor metastasis. Annu. Rev. Med. 49 (1998), 407–424.
23. Kobayashi, Y., Nakajima, T., Saku, T., Loss of basement membranes in the invading front of O-1N, hamster squamous cell carcinoma with high potential of lymph node metastasis: an immunohistochemical study for laminin and type IV collagen. Pathol. Int. 45 (1995), 327–334.
24. Kang, S.G., Ha, Y.R., Ko, Y.H., Kang, S.H., Joo, K.J., Cho, H.Y., et al. Effect of laminin 332 on motility and invasion in bladder cancer. Kaohsiung J. Med. Sci. 29 (2013), 422–429.
25. Rani, V., McCullough, M., Chandu, A., Assessment of laminin-5 in oral dysplasia and squamous cell carcinoma. J. Oral Maxillofac. Surg. 71 (2013), 1873–1879.
26. Zhou, B., Gibson-Corley, K.N., Herndon, M.E., Sun, Y., Gustafson-Wagner, E., Teoh-Fitzgerald, M., et al. Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol. Cancer Res. 12 (2014), 143–154.
27. Peixoto da-Silva, J., Lourenco, S., Nico, M., Silva, F.H., Martins, M.T., Costa-Neves, A., Expression of laminin-5 and integrins in actinic cheilitis and superficially invasive squamous cell carcinomas of the lip. Pathol. Res. Pract. 208 (2012), 598–603.
28. Marinkovich, M.P., Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat. Rev. Cancer 7 (2007), 370–380.
29. van der Zee, J.A., van Eijck, C.H., Hop, W.C., Biermann, K., Dicheva, B.M., Seynhaeve, A.L., et al. Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer. Br. J. Cancer 107 (2012), 1153–1158.
30. Ogawa, M., Ikeuchi, K., Watanabe, M., Etoh, K., Kobayashi, T., Takao, Y., et al. Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology 52 (2005), 875–880.
31. Orita, H., Korenaga, D., Maehara, Y., Baba, H., Sugimachi, K., Laminin distribution patterns are closely related to liver metastasis in gastric cancer. Cancer 71 (1993), 1201–1206.
32. Mori, T., Kariya, Y., Komiya, E., Higashi, S., Miyagi, Y., Sekiguchi, K., et al. Downregulation of a newly identified laminin, laminin-3B11, in vascular basement membranes of invasive human breast cancers. Cancer Sci. 102 (2011), 1095–1100.
33. Korbakis, D., Dimitromanolakis, A., Prassas, I., Davis, G.J., Barber, E., Reckamp, K.L., et al. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. Br. J. Cancer 113 (2015), 484–491.
34. Saito, N., Kameoka, S., Serum laminin is an independent prognostic factor in colorectal cancer. Int. J. Colorectal Dis. 20 (2005), 238–244.
35. Aghcheli, K., Parsian, H., Qujeq, D., Talebi, M., Mosapour, A., Khalilipour, E., et al. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. Eur. J. Intern. Med. 23 (2012), 58–64.
36. Liu, W., Tian, F., Jiang, P., Zhao, X., Guo, F., Li, X., et al. Aberrant expression of laminin gamma2 correlates with poor prognosis and promotes invasion in extrahepatic cholangiocarcinoma. J. Surg. Res. 186 (2014), 150–156.
37. Takahashi, S., Hasebe, T., Oda, T., Sasaki, S., Kinoshita, T., Konishi, M., et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 94 (2002), 1894–1901.
38. Kosanam, H., Prassas, I., Chrystoja, C.C., Soleas, I., Chan, A., Dimitromanolakis, A., et al. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol. Cell. Proteomics 12 (2013), 2820–2832.
39. Fukazawa, S., Shinto, E., Tsuda, H., Ueno, H., Shikina, A., Kajiwara, Y., et al. Laminin beta3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer. Jpn. J. Clin. Oncol. 45 (2015), 533–540.
40. Bizama, C., Benavente, F., Salvatierra, E., Gutierrez-Moraga, A., Espinoza, J.A., Fernandez, E.A., et al. The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer. Int. J. Cancer 134 (2014), 755–764.
41. Ke, H.L., Ke, R.H., Li, B., Wang, X.H., Wang, Y.N., Wang, X.Q., Association between laminin gamma1 expression and meningioma grade, recurrence, and progression-free survival. Acta Neurochir. (Wien) 155 (2013), 165–171.
42. Petz, M., Them, N., Huber, H., Beug, H., Mikulits, W., La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic Acids Res. 40 (2012), 290–302.
43. Drake, J.M., Barnes, J.M., Madsen, J.M., Domann, F.E., Stipp, C.S., Henry, M.D., ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells. J. Biol. Chem. 285 (2010), 33940–33948.
44. Denoyer, D., Kusuma, N., Burrows, A., Ling, X., Jupp, L., Anderson, R.L., et al. Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells. Growth Factors 32 (2014), 63–73.
45. Kusuma, N., Denoyer, D., Eble, J.A., Redvers, R.P., Parker, B.S., Pelzer, R., et al. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int. J. Cancer 130 (2012), 555–566.
46. Garg, M., Kanojia, D., Okamoto, R., Jain, S., Madan, V., Chien, W., et al. Laminin-5gamma-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J. Clin. Endocrinol. Metab. 99 (2014), E62–72.
47. Degen, M., Natarajan, E., Barron, P., Widlund, H.R., Rheinwald, J.G., MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin gamma2 expression in oral dysplasia and squamous cell carcinoma. Am. J. Pathol. 180 (2012), 2462–2478.
48. Kinoshita, T., Hanazawa, T., Nohata, N., Kikkawa, N., Enokida, H., Yoshino, H., et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 3 (2012), 1386–1400.
49. Kinoshita, T., Nohata, N., Hanazawa, T., Kikkawa, N., Yamamoto, N., Yoshino, H., et al. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br. J. Cancer 109 (2013), 2636–2645.
50. Nishikawa, R., Goto, Y., Kojima, S., Enokida, H., Chiyomaru, T., Kinoshita, T., et al. Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int. J. Oncol. 45 (2014), 401–410.
51. Hanaki, H., Yamamoto, H., Sakane, H., Matsumoto, S., Ohdan, H., Sato, A., et al. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol. Cancer Ther. 11 (2012), 298–307.
52. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
53. Meacham, C.E., Morrison, S.J., Tumour heterogeneity and cancer cell plasticity. Nature 501 (2013), 328–337.
54. Lu, P., Takai, K., Weaver, V.M., Werb, Z., Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol., 3, 2011.
55. Laperle, A., Hsiao, C., Lampe, M., Mortier, J., Saha, K., Palecek, S.P., et al. Alpha-5 laminin synthesized by human pluripotent stem cells promotes self-renewal. Stem Cell Rep. 5 (2015), 195–206.
56. Ma, W., Tavakoli, T., Derby, E., Serebryakova, Y., Rao, M.S., Mattson, M.P., Cell-extracellular matrix interactions regulate neural differentiation of human embryonic stem cells. BMC Dev. Biol., 8, 2008, 90.
57. Qu, H., Liu, X., Ni, Y., Jiang, Y., Feng, X., Xiao, J., et al. Laminin 411 acts as a potent inducer of umbilical cord mesenchymal stem cell differentiation into insulin-producing cells. J. Transl. Med., 12, 2014, 135.
58. Lin, H.Y., Tsai, C.C., Chen, L.L., Chiou, S.H., Wang, Y.J., Hung, S.C., Fibronectin and laminin promote differentiation of human mesenchymal stem cells into insulin producing cells through activating Akt and ERK. J. Biomed. Sci., 17, 2010, 56.
59. Sa, S., Wong, L., McCloskey, K.E., Combinatorial fibronectin and laminin signaling promote highly efficient cardiac differentiation of human embryonic stem cells. Biores. Open Access. 3 (2014), 150–161.
60. Bergstrom, R., Strom, S., Holm, F., Feki, A., Hovatta, O., Xeno-free culture of human pluripotent stem cells. Methods Mol. Biol. 767 (2011), 125–136.
61. Miyazaki, T., Futaki, S., Suemori, H., Taniguchi, Y., Yamada, M., Kawasaki, M., et al. Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat. Commun., 3, 2012, 1236.
62. Simonson, O.E., Domogatskaya, A., Volchkov, P., Rodin, S., The safety of human pluripotent stem cells in clinical treatment. Ann. Med. 47 (2015), 370–380.
63. Scheele, S., Falk, M., Franzen, A., Ellin, F., Ferletta, M., Lonai, P., et al. Laminin alpha1 globular domains 4–5 induce fetal development but are not vital for embryonic basement membrane assembly. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 1502–1506.
64. Horejs, C.M., Serio, A., Purvis, A., Gormley, A.J., Bertazzo, S., Poliniewicz, A., et al. Biologically-active laminin-111 fragment that modulates the epithelial-to-mesenchymal transition in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5908–5913.
65. Jin, L., Feng, T., Shih, H.P., Zerda, R., Luo, A., Hsu, J., et al. Colony-forming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine/acinar colonies in laminin hydrogel. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3907–3912.
66. Plaza Reyes, A., Petrus-Reurer, S., Antonsson, L., Stenfelt, S., Bartuma, H., Panula, S., et al. Xeno-free and defined human embryonic stem cell-derived retinal pigment epithelial cells functionally integrate in a large-eyed preclinical model. Stem Cell Rep. 6 (2016), 9–17.
67. Noro, A., Sillat, T., Virtanen, I., Ingerpuu, S., Back, N., Konttinen, Y.T., et al. Laminin production and basement membrane deposition by mesenchymal stem cells upon adipogenic differentiation. J. Histochem. Cytochem. 61 (2013), 719–730.
68. Mruthyunjaya, S., Manchanda, R., Godbole, R., Pujari, R., Shiras, A., Shastry, P., Laminin-1 induces neurite outgrowth in human mesenchymal stem cells in serum/differentiation factors-free conditions through activation of FAK-MEK/ERK signaling pathways. Biochem. Biophys. Res. Commun. 391 (2010), 43–48.
69. Salasznyk, R.M., Klees, R.F., Boskey, A., Plopper, G.E., Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin-5. J. Cell. Biochem. 100 (2007), 499–514.
70. Hashimoto, J., Kariya, Y., Miyazaki, K., Regulation of proliferation and chondrogenic differentiation of human mesenchymal stem cells by laminin-5 (laminin-332). Stem Cells 24 (2006), 2346–2354.
71. Damjanov, I., The road from teratocarcinoma to human embryonic stem cells. Stem Cell Rev. 1 (2005), 273–276.
72. Lehtonen, E., Laasonen, A., Tienari, J., Teratocarcinoma stem cells as a model for differentiation in the mouse embryo. Int. J. Dev. Biol. 33 (1989), 105–115.
73. Datta, P.K., Budhiraja, S., Reichel, R.R., Jacob, S.T., Regulation of ribosomal RNA gene transcription during retinoic acid-induced differentiation of mouse teratocarcinoma cells. Exp. Cell Res. 231 (1997), 198–205.
74. Li, C., Gudas, L.J., Murine laminin B1 gene regulation during the retinoic acid- and dibutyryl cyclic AMP-induced differentiation of embryonic F9 teratocarcinoma stem cells. J. Biol. Chem. 271 (1996), 6810–6818.
75. Espeseth, A.S., Murphy, S.P., Linney, E., Retinoic acid receptor expression vector inhibits differentiation of F9 embryonal carcinoma cells. Genes Dev. 3 (1989), 1647–1656.
76. Grover, A., Edwards, S.A., Bourdon, M., Adamson, E.D., Proteoglycan-19, laminin and collagen type IV production is correlated with the levels of mRNA in F9 cell aggregates differentiating in the presence or absence of cyclic AMP. Differentiation 36 (1987), 138–144.
77. Hanahan, D., Coussens, L.M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 (2012), 309–322.
78. Ross, J.B., Huh, D., Noble, L.B., Tavazoie, S.F., Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat. Cell Biol. 17 (2015), 651–664.
79. Govaere, O., Wouters, J., Petz, M., Vandewynckel, Y.P., Van den Eynde, K., Van den Broeck, A., et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J. Hepatol. 64:3 (2016), 609–617.
80. Lathia, J.D., Li, M., Hall, P.E., Gallagher, J., Hale, J.S., Wu, Q., et al. Laminin alpha 2 enables glioblastoma stem cell growth. Ann. Neurol. 72 (2012), 766–778.
81. Niibori-Nambu, A., Midorikawa, U., Mizuguchi, S., Hide, T., Nagai, M., Komohara, Y., et al. Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin alphaV. PLoS One, 8, 2013, e59558.
82. Chang, C., Goel, H.L., Gao, H., Pursell, B., Shultz, L.D., Greiner, D.L., et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the alpha6Bbeta1 integrin to sustain breast cancer stem cells. Genes Dev. 29 (2015), 1–6.
83. Buchstaller, J., McKeever, P.E., Morrison, S.J., Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell 21 (2012), 240–252.
84. Guzman-Ramirez, N., Voller, M., Wetterwald, A., Germann, M., Cross, N.A., Rentsch, C.A., et al. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 69 (2009), 1683–1693.
85. Verfaillie, C.M., McCarthy, J.B., McGlave, P.B., Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 90 (1992), 1232–1241.
86. Saha, S., Lo, P.K., Duan, X., Chen, H., Wang, Q., Breast tumour initiating cell fate is regulated by microenvironmental cues from an extracellular matrix. Integr. Biol. (Camb.) 4 (2012), 897–904.
87. Rahman, M., Reyner, K., Deleyrolle, L., Millette, S., Azari, H., Day, B.W., et al. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. Anat. Cell Biol. 48 (2015), 25–35.
88. Watanabe, Y., Yoshimura, K., Yoshikawa, K., Tsunedomi, R., Shindo, Y., Matsukuma, S., et al. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Int. J. Oncol. 45 (2014), 1857–1866.
89. Morel, A.P., Lievre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A., Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3, 2008, e2888.
90. Ritie, L., Spenle, C., Lacroute, J., Bolcato-Bellemin, A.L., Lefebvre, O., Bole-Feysot, C., et al. Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice. PLoS One, 7, 2012, e37710.
91. Estrach, S., Cailleteau, L., Franco, C.A., Gerhardt, H., Stefani, C., Lemichez, E., et al. Laminin-binding integrins induce Dll4 expression and Notch signaling in endothelial cells. Circ. Res. 109 (2011), 172–182.
92. Borah, A., Raveendran, S., Rochani, A., Maekawa, T., Kumar, D.S., Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy. Oncogenesis, 4, 2015, e177.
93. Tsuruta, D., Kobayashi, H., Imanishi, H., Sugawara, K., Ishii, M., Jones, J.C., Laminin-332-integrin interaction: a target for cancer therapy. Curr. Med. Chem. 15 (2008), 1968–1975.
94. Landowski, T.H., Gard, J., Pond, E., Pond, G.D., Nagle, R.B., Geffre, C.P., et al. Targeting integrin alpha6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol. Cancer Ther. 13 (2014), 1558–1566.
95. Miftakhova, R., Hedblom, A., Semenas, J., Robinson, B.D., Simoulis, A., Malm, J., et al. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 76:8 (2016), 2453–2464.
96. Urakawa, H., Nishida, Y., Wasa, J., Arai, E., Zhuo, L., Kimata, K., et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int. J. Cancer 130 (2012), 454–466.
97. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
98. Vansteenkiste, J., Barlesi, F., Waller, C.F., Bennouna, J., Gridelli, C., Goekkurt, E., et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann. Oncol. 26 (2015), 1734–1740.
99. Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., Hong, Y.K., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15 (2014), 1100–1108.
100. De Santis, R., Albertoni, C., Petronzelli, F., Campo, S., D'Alessio, V., Rosi, A., et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin. Cancer Res. 12 (2006), 2191–2196.
101. Smith, C.L., Chaichana, K.L., Lee, Y.M., Lin, B., Stanko, K.M., O'Donnell, T., et al. Pre-exposure of human adipose mesenchymal stem cells to soluble factors enhances their homing to brain cancer. Stem Cells Trans. Med. 4 (2015), 239–251.